CLBIO logo

Corline Biomedical AB Stock Price

OM:CLBIO Community·SEK 454.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

CLBIO Share Price Performance

SEK 0
-13.85 (-100.00%)
SEK 0
-13.85 (-100.00%)
Price SEK 0

CLBIO Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

Corline Biomedical AB Key Details

SEK 10.7m

Revenue

SEK 1.8m

Cost of Revenue

SEK 8.8m

Gross Profit

SEK 23.0m

Other Expenses

-SEK 14.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.54
82.81%
-132.61%
0%
View Full Analysis

About CLBIO

Founded
1991
Employees
13
CEO
Henrik Nittmar
WebsiteView website
www.corline.se

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Recent CLBIO News & Updates

Analysis Article May 11

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

No updates